Uptake Medical

A selection of Uptake Medical's published studies

Seattle, WA - Uptake Medical Inc, the developer of the InterVapor System for Bronchoscopic Thermal Vapor Ablation (BTVA), today announced the inclusion of BTVA in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructiv

Seattle, WA -- The InterVapor Bronchoscopic Thermal Vapor Ablation (BTVA) is back on the market after a brief hiatus as the asset sale of Uptake Medical Corporation was being completed to Broncus Holding Co. A new company, Uptake Medical Technology, Inc was formed in Seattle, WA, USA and has rece

SAN JOSE, Calif.--( BUSINESS WIRE )-- Broncus Medical , Inc., developer of diagnostic and therapeutic technology for a variety of lung diseases, today announced publication of results from the VAPORIZE study in the current issue of Respiration. The feasibility study reported on the use of bronchosco

Broncus Medical published VAPORIZE study results in *Respiration*, showing bronchoscopic thermal vapor ablation (BTVA) can ablate lung tumors.

Uptake Medical Technology, Inc. relaunches the InterVapor Bronchoscopic Thermal Vapor Ablation (BTVA) system for treating severe emphysema after acquiring the technology from Uptake Medical Corporation. The device, now CE Mark-certified, demonstrates clinically meaningful improvements in pulmonary function and quality of life for patients. The company operates out of Seattle, Washington.

Sep 2017PR NewswireNews article

Broncus Holding Company (BHC) acquires Uptake Medical Corp, a manufacturer of vapor technology for bronchoscopic ablation of emphysema and lung cancer. The technology demonstrates clinically meaningful improvements in lung function and quality of life, as shown in a randomized controlled trial published in *The Lancet Respiratory Medicine* (July 2016). The deal strengthens BHC’s position in lung disease treatment innovations.

Sep 2016PR NewswireNews article

Uptake Medical reports that its Intervapor targeted ablation therapy achieves statistically significant improvements in severe emphysema patients compared to standard medical management. The findings, published in *The Lancet*, stem from the Phase 3 **STEP-UP** trial, which evaluated lung function and quality-of-life metrics. The therapy targets lung tissue damage reduction, offering a potential alternative for patients with advanced disease.

Mar 2016BioSpaceNews article

Uptake Medical reports that patients using its InterVapor system show statistically significant improvements in lung function and quality of life, according to a study published in *Lancet*. The findings highlight the system’s potential for respiratory therapy outcomes.

Mar 2016MassDeviceNews article